Panacea Biotec

388.00
-7.40
(-1.87%)
ann
There are new updates from the company15 hours ago
Viewcross
right
Market Cap
2,376.53 Cr
EPS
-0.19
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
490.55
52 Week low
112.35
PB Ratio
2.92
Debt to Equity
0.02
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,666.40 3,99,825.18 33.68 49,887.20 12.06 9,648 13.77 47.46
5,509.80 1,46,267.88 71.18 8,184.00 0.89 1,600 64.53 40.99
1,452.15 1,17,277.67 23.41 26,520.70 14.17 4,155 47.38 48.78
3,081.95 1,04,307.19 55.61 10,785.70 11.59 1,656 13.54 47.28
1,094.65 91,338.79 17.35 28,905.40 12.36 5,578 1.69 31.30
2,168.00 89,444.50 44.67 10,615.60 19.57 1,942 -16.38 33.38
1,954.35 89,156.97 31.45 20,141.50 19.94 1,936 38.82 44.40
878.55 88,402.69 19.97 19,831.50 13.82 3,831 29.92 45.15
30,244.05 64,266.50 48.58 6,097.20 10.80 1,201 16.01 58.42
1,102.75 64,047.90 17.97 29,559.20 17.55 3,169 -10.04 42.48
Growth Rate
Revenue Growth
14.35 %
Net Income Growth
-95.55 %
Cash Flow Change
99.98 %
ROE
-95.52 %
ROCE
-70.49 %
EBITDA Margin (Avg.)
-110.83 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
123
122
114
485
131
129
171
144
134
184
144
173
136
234
158
1,821
151
143
157
163
163
149
159
150
122
155
170
Expenses
116
179
87
258
104
149
132
150
111
144
127
167
134
226
144
171
191
109
124
135
140
147
151
143
130
140
156
EBITDA
7
-57
27
228
27
-20
39
-6
23
40
17
6
2
8
14
1,650
-40
34
33
29
24
2
8
8
-8
14
14
Operating Profit %
-17 %
-48 %
21 %
-110 %
17 %
-19 %
21 %
-19 %
16 %
21 %
11 %
1 %
-1 %
3 %
8 %
-21 %
-72 %
-4 %
-8 %
-4 %
-8 %
-2 %
-0 %
-4 %
-12 %
5 %
5 %
Depreciation
14
14
52
13
11
11
11
10
11
11
11
12
11
11
11
11
10
10
10
10
10
9
9
9
9
9
9
Interest
25
29
-14
26
41
42
47
45
45
48
46
47
48
50
52
31
1
1
1
1
1
1
1
1
1
1
1
Profit Before Tax
-33
-99
-11
189
-25
-73
-19
-61
-34
-19
-40
-53
-57
-53
-49
1,608
-51
23
22
18
13
-8
-2
-2
-17
5
4
Tax
3
-2
5
3
3
2
2
9
0
0
0
2
0
0
0
371
5
8
3
31
2
1
1
-0
-1
0
-0
Net Profit
-35
-97
-16
186
-28
-75
-21
-70
-34
-19
-40
-54
-57
-53
-49
1,238
-56
16
19
-13
11
-8
-2
-2
-16
5
4
EPS in ₹
-5.75
-15.83
-2.60
30.35
-4.62
-12.25
-3.48
-11.38
-5.58
-3.16
-6.54
-8.84
-9.36
-8.65
-8.03
202.03
-9.17
2.56
3.16
-2.03
1.79
-1.35
-0.37
-0.23
-2.59
0.77
0.74

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,931
1,854
1,800
1,608
1,376
1,390
1,178
1,759
1,271
1,241
Fixed Assets
1,144
1,071
1,001
949
806
657
609
622
600
582
Current Assets
526
549
533
560
508
683
511
951
562
485
Capital Work in Progress
156
161
30
40
23
24
34
17
42
102
Investments
5
4
7
7
5
6
0
5
14
40
Other Assets
626
619
761
611
542
703
534
1,115
615
517
Total Liabilities
1,931
1,854
1,800
1,608
1,376
1,390
1,178
1,759
1,271
1,241
Current Liabilities
706
475
588
691
938
452
449
776
330
309
Non Current Liabilities
750
930
846
611
90
743
960
109
101
94
Total Equity
475
450
366
306
347
196
-232
874
840
838
Reserve & Surplus
449
426
340
293
335
139
-257
849
816
814
Share Capital
22
22
6
6
6
6
6
6
6
6

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-1
-10
-2
9
-2
26
12
-2
-11
7
Investing Activities
-37
17
-26
55
-6
-35
-48
1,283
430
10
Operating Activities
37
91
131
118
105
-31
107
-108
-423
-0
Financing Activities
-1
-117
-107
-164
-101
91
-47
-1,176
-18
-3

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.46 %
72.87 %
72.49 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.27 %
0.27 %
0.37 %
0.38 %
DIIs
1.27 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.29 %
0.43 %
0.43 %
0.54 %
0.00 %
0.00 %
0.84 %
1.07 %
1.16 %
1.17 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
17.34 %
15.21 %
15.57 %
15.99 %
15.14 %
15.60 %
15.79 %
15.97 %
15.82 %
16.15 %
19.20 %
19.63 %
19.90 %
20.42 %
18.11 %
18.98 %
Others
7.80 %
11.20 %
10.84 %
10.42 %
11.27 %
10.81 %
10.33 %
10.02 %
10.16 %
9.73 %
7.21 %
6.78 %
5.40 %
4.79 %
7.49 %
6.99 %
No of Share Holders
27,228
54,313
52,816
52,465
49,563
49,896
49,078
50,533
48,634
47,815
48,878
47,091
46,242
45,513
39,982
35,446

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Announcements

Clarification sought from Panacea Biotec Ltd
15 hours ago
Demat Report For The Month Of February 2025
7 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication
Feb 28, 2025, 17:32
Announcement under Regulation 30 (LODR)-Newspaper Publication
Feb 28, 2025, 17:32
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Feb 27, 2025, 16:26
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Feb 27, 2025, 16:26
Announcement under Regulation 30 (LODR)-Newspaper Publication
Feb 15, 2025, 13:59
Announcement under Regulation 30 (LODR)-Change in Directorate
Feb 15, 2025, 24:12
Integrated Filing (Financial)
Feb 14, 2025, 19:40
Announcement under Regulation 30 (LODR)-Change in Management
Feb 14, 2025, 18:49
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31 2024
Feb 14, 2025, 18:42
Board Meeting Outcome for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2024 2. Appointment / Re-Appointment Of Directors 3. Change In Senior Management Personnel 4. Re
Feb 14, 2025, 18:32
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 13, 2025, 17:19
Demat Report For The Month Of January 2025
Feb 07, 2025, 15:49
Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended December 31 2024
Jan 31, 2025, 14:40
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations)
Jan 23, 2025, 15:18
Details Of Shares Dematerialized During December 2024
Jan 07, 2025, 16:53
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 07, 2025, 15:08
Intimation Regarding Launch Of Baby Diapers And Wipes By CompanyS Wholly-Owned Subsidiary Panacea Biotec Pharma Limited
Jan 03, 2025, 15:05
Announcement under Regulation 30 (LODR)-Change in Management
Jan 01, 2025, 11:23
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Dec 28, 2024, 16:42
Intimation Of Further Investment In Panacea Biotec Inc. Made By The CompanyS Material Subsidiary Panacea Biotec Pharma Limited
Dec 28, 2024, 12:59
Announcement under Regulation 30 (LODR)-Change in Management
Dec 09, 2024, 18:18
Details Of Shares Dematerialized During November 2024
Dec 06, 2024, 10:53
Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 27, 2024, 17:56
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Nov 26, 2024, 12:21
Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 14, 2024, 15:14
Announcement under Regulation 30 (LODR)-Change in Directorate
Nov 13, 2024, 16:11
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2024
Nov 13, 2024, 15:51
Board Meeting Outcome for Outcome Of Board Meeting Held On November 13, 2024
Nov 13, 2024, 15:46
Intimation Regarding:(A) Appointment Of Independent Director In The Company'S Unlisted Material Subsidiary Company Viz. Panacea Biotec Pharma Limited; And(B) Corporate Guarantee Proposed To Be Given By PBPL For Proposed Fund Raising By Panacea Biotec Limited By Way Of External Commercial Borrowings
Nov 12, 2024, 17:57
Details Of Share Dematerialised For The Month Of October, 2024Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
Nov 08, 2024, 17:41
Update on board meeting
Nov 08, 2024, 17:32
Board Meeting Intimation for Approving Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And HalfYear Ended September 30, 2024
Oct 30, 2024, 13:55
Announcement under Regulation 30 (LODR)-Demise
Oct 16, 2024, 18:18
Intimation Under Regulation 30 Read With 31A Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Regarding Submission Of Application For Reclassification From 'Promoters & Promoters' Group' Category To 'Public' Category Of Panacea Biotec Limited
Oct 16, 2024, 16:32
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Oct 14, 2024, 17:42
Details Of Share Dematerialised For The Month Of September, 2024 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
Oct 07, 2024, 16:33
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Sep 28, 2024, 18:49
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Sep 27, 2024, 16:40
Shareholder Meeting / Postal Ballot-Outcome of AGM
Sep 27, 2024, 16:15
Appointment Of M/S Suresh Surana & Associates LLP As Statutory Auditors Of Material Subsidiary Viz. Panacea Biotec Pharma Limited
Sep 26, 2024, 18:10
Closure of Trading Window
Sep 26, 2024, 18:02
Intimation Of Disposal Of Suit Filed By Panacea Biotec Limited ('Company') Against Sanofi Healthcare India Private Limited Pursuant To Settlement Between The Parties
Sep 16, 2024, 21:26
Communication Sent To Physical Shareholders To Furnish PAN And KYC Details
Sep 13, 2024, 16:35
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sep 12, 2024, 15:28
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Sep 09, 2024, 12:04
Details Of Shares Dematerialized During August 2024Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
Sep 06, 2024, 17:23
Announcement under Regulation 30 (LODR)-Newspaper Publication
Sep 06, 2024, 17:10
Reg. 34 (1) Annual Report.
Sep 05, 2024, 22:40

Company Filings to Exchanges

Technical Indicators

RSI(14)
Neutral
61.14
ATR(14)
Less Volatile
27.91
STOCH(9,6)
Neutral
79.73
STOCH RSI(14)
Overbought
100.00
MACD(12,26)
Bullish
10.64
ADX(14)
Weak Trend
22.97
UO(9)
Bearish
54.85
ROC(12)
Uptrend And Accelerating
20.31
WillR(14)
Overbought
-11.74